Wavelength-Pharmaceuticals-Insert
X

Find Novel Oncology Drugs in Preclinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OP-1250

            Therapeutic Area: Oncology Product Name: OP-1250

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: BVF Partners L.P

            Deal Size: $54.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 22, 2020

            Details:

            Proceeds will be used to advance OP-1250, the Company's lead program in breast cancer, into Phase 1/2 clinical development and expand ongoing research and development activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GMcSF,Interleukins 18

            Therapeutic Area: Oncology Product Name: SON-2014

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            Data provide proof-of-concept for advancing SON-2014, a bispecific combination of GMcSF and IL-18.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KB-0742

            Therapeutic Area: Oncology Product Name: KB-0742

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 09, 2020

            Details:

            Results showed that KB-0742 inhibited tumor growth in a prostate xenograft model, as well as other cancers addicted to high levels of oncogenic transcription.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VOR33

            Therapeutic Area: Oncology Product Name: VOR33

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $110.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 07, 2020

            Details:

            The series B financing Proceeds will advance the company’s lead candidate VOR33 into clinical trials, deepen its portfolio, and accelerate the validation of additional targets for its scientific platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Alphale-Exatecan

            Therapeutic Area: Oncology Product Name: CBX-12

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            The Phase I portion of the study will establish the safety profile and a recommended Phase II dose (RP2D). This initial clinical trial will also evaluate efficacy across a number of solid tumors and establish proof of mechanism for the alphalex™ platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 6-thio-2-deoxyguanosine,Anti-PD-L1 therapy

            Therapeutic Area: Oncology Product Name: Thio

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SNS-510

            Therapeutic Area: Oncology Product Name: SNS-510

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            The changes will extend Sunesis's cash runway and provide it with the necessary resources to execute on its PDK1 program evaluating its PDK1 inhibitor SNS-510, while also allowing the flexibility to explore opportunities for additional value creation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NKX101

            Therapeutic Area: Oncology Product Name: NKX101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Cowen

            Deal Size: $150.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering July 02, 2020

            Details:

            Nkarta Therapeutics is working on off-the-shelf cancer therapies based on natural killer cells. The net proceeds will support the growth of company's pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WP1066,Whole brain radiation therapy

            Therapeutic Area: Oncology Product Name: WP1066

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            The article reported findings that Moleculin's STAT3 inhibitor, WP1066, used in combination with traditional whole brain radiation therapy resulted in long-term survivors and enhanced median survival time relative to monotherapy in mice with implanted human brain tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ST-067

            Therapeutic Area: Oncology Product Name: ST-067

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: WuXi AppTec Inc.

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 24, 2020

            Details:

            Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.

            PharmaCompass